CN113645968A - 治疗胃肠疾病和障碍的组合物和方法 - Google Patents

治疗胃肠疾病和障碍的组合物和方法 Download PDF

Info

Publication number
CN113645968A
CN113645968A CN202080019649.1A CN202080019649A CN113645968A CN 113645968 A CN113645968 A CN 113645968A CN 202080019649 A CN202080019649 A CN 202080019649A CN 113645968 A CN113645968 A CN 113645968A
Authority
CN
China
Prior art keywords
rifaximin
mucolytic agent
rifamycin
ibs
nac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080019649.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·皮门特尔
G·G·S·莱特
R·马图尔
A·莱扎伊
W·莫拉莱斯
S·魏茨曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of CN113645968A publication Critical patent/CN113645968A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080019649.1A 2019-03-18 2020-03-18 治疗胃肠疾病和障碍的组合物和方法 Pending CN113645968A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819986P 2019-03-18 2019-03-18
US62/819,986 2019-03-18
PCT/US2020/023396 WO2020191076A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Publications (1)

Publication Number Publication Date
CN113645968A true CN113645968A (zh) 2021-11-12

Family

ID=72520533

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080019649.1A Pending CN113645968A (zh) 2019-03-18 2020-03-18 治疗胃肠疾病和障碍的组合物和方法

Country Status (7)

Country Link
US (1) US20230038019A1 (https=)
EP (1) EP3941461A4 (https=)
JP (1) JP2022526495A (https=)
CN (1) CN113645968A (https=)
AU (2) AU2020240069B2 (https=)
CA (2) CA3132400A1 (https=)
WO (1) WO2020191076A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205650A1 (en) * 2022-04-20 2023-10-26 Cedars-Sinai Medical Center Methods of diagnosing ibs-d and selection of ibs-d treatment
US20250275950A1 (en) * 2022-05-19 2025-09-04 Cedars-Sinai Medical Center Rifaximin and n-acetyl cysteine formulations

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1235529A (en) * 1968-12-02 1971-06-16 Calbiochem Composition for mucolysis
TWI236905B (en) * 1997-10-28 2005-08-01 Jens Ponikau Pharmaceutical composition for treating and preventing inflammation of mucosal tissue
CN1874757A (zh) * 2003-09-15 2006-12-06 维克特拉有限公司 治疗肺病的粘液活性剂
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
US20080194456A1 (en) * 2004-04-09 2008-08-14 The General Hospital Corporation Compositions And Methods Related To An Intestinal Inflammation And Uses Therefor
US20120088902A1 (en) * 2006-06-29 2012-04-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20150307530A1 (en) * 2012-08-31 2015-10-29 Parion Sciences, Inc. Novel mucolytic agents
US20170209530A1 (en) * 2014-07-25 2017-07-27 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
CN107308186A (zh) * 2010-02-03 2017-11-03 微生物公司 作为抗菌剂用于包括细菌生物膜的治疗的生物医学用途以及其它用途的铋‑硫醇
WO2018148113A1 (en) * 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264409A1 (en) * 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
GB0823472D0 (en) * 2008-12-23 2009-01-28 Photocure Asa Product
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
WO2014070769A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
US20160158262A1 (en) * 2013-07-26 2016-06-09 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
DK3288554T3 (da) * 2015-04-30 2022-11-14 Probiotical Spa Anvendelse af antibiotika med specifikke terapeutiske aktiviteter kombineret med samtidig anvendelse af lactobacilli og/eller bifidobakterier med en ikke-overførbar antibiotisk resistens med den samme terapeutiske indikation

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1235529A (en) * 1968-12-02 1971-06-16 Calbiochem Composition for mucolysis
TWI236905B (en) * 1997-10-28 2005-08-01 Jens Ponikau Pharmaceutical composition for treating and preventing inflammation of mucosal tissue
CN1874757A (zh) * 2003-09-15 2006-12-06 维克特拉有限公司 治疗肺病的粘液活性剂
US20080194456A1 (en) * 2004-04-09 2008-08-14 The General Hospital Corporation Compositions And Methods Related To An Intestinal Inflammation And Uses Therefor
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
US20120088902A1 (en) * 2006-06-29 2012-04-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN107308186A (zh) * 2010-02-03 2017-11-03 微生物公司 作为抗菌剂用于包括细菌生物膜的治疗的生物医学用途以及其它用途的铋‑硫醇
US20150307530A1 (en) * 2012-08-31 2015-10-29 Parion Sciences, Inc. Novel mucolytic agents
US20170209530A1 (en) * 2014-07-25 2017-07-27 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
WO2018148113A1 (en) * 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAHMAN KHAMENEH ET AL.: "Combination of anti-tuberculosis drugs with vitamin C or NAC against different staphylococcus aureus and mycobacterium tuberculosis strains", 《MICROBIAL PATHOGENESIS》, vol. 93, pages 83 - 87 *
STEVEN SANDBERG-LEWIS ET AL.: "SIBO:Dysbiosis has a new name", 《BEST OF NATUROPATHIC MEDICINE》, pages 67 - 76 *

Also Published As

Publication number Publication date
EP3941461A4 (en) 2022-12-14
AU2020240069A1 (en) 2021-10-28
CA3293273A1 (en) 2026-03-02
AU2025271108A1 (en) 2025-12-18
EP3941461A1 (en) 2022-01-26
US20230038019A1 (en) 2023-02-09
CA3132400A1 (en) 2020-09-24
JP2022526495A (ja) 2022-05-25
WO2020191076A1 (en) 2020-09-24
AU2020240069B2 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
Russo et al. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial
Rasmussen et al. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis
AU2025271108A1 (en) Compositions and methods to treat gastrointestinal diseases and disorders
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
JP2014504610A (ja) 脂肪異栄養症の処置
US20210338749A1 (en) Methods of treatment of inflammatory conditions and associated infections
RU2672871C2 (ru) Применение левоцетиризина и монтелукаста при лечении травматических повреждений
TW201806604A (zh) ９－胺甲基米諾四環素化合物及其治療尿路感染（ｕｔｉ）之使用方法
US20230081059A1 (en) Method of treatment and prevention of bacterial vaginosis
Tirado-Miranda et al. Septic arthritis due to Scedosporium apiospermum: case report and review
WO2016120787A1 (en) Oral n-acetylcysteine in the treatment of upper respiratory tract infections and symptoms
US20240366550A1 (en) Drug for Treating Prostatitis or Benign Prostatic Hyperplasia (BPH)
HK40064209A (en) Compositions and methods to treat gastrointestinal diseases and disorders
Horsley et al. Cystic fibrosis
Swatesutipun Can recurrent UTIs in women be cured? Review article
EP3554489A1 (en) Treatment of moderate and severe gastroparesis
Chua Metronidazole
UA123705C2 (uk) Лікарський засіб для лікування інфекцій на фоні діабетичної стопи
CN112888437A (zh) 加波沙朵在治疗胃肠道紊乱和哮喘中的用途
CN116940350A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
Gehanno et al. Moxifloxacin in the treatment of acute maxillary sinusitis after first-line treatment failure and acute sinusitis with high risk of complications
RU2391977C2 (ru) Способ лечения острых форм бактериальных вагинитов
Wilson et al. Comparison of the Effectiveness of Oral and Intravenous Antibiotics for the Treatment of Acute Sinusitis in Children at Skopje Hospital, Macedonia
Webb Diagnosis of acute rheumatic fever
Zhou et al. Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064209

Country of ref document: HK